Skip to main content
. Author manuscript; available in PMC: 2020 Jun 15.
Published in final edited form as: Ann Breast Cancer Ther. 2020 May 2;4(1):48–57. doi: 10.36959/739/525

Figure 1: SIAH is a binary, tumor-specific, therapy-responsive, and prognostic biomarker in breast cancer.

Figure 1:

SIAHON/OFF expression in residual tumors can be used to stratify patients, identify good prognosis (SIAH expression is absent or low) or poor prognosis (SIAH expression is high), forecast early tumor relapse, predict patient survival with post-neoadjuvant chemotherapy (NACT).